This is an interview with Kyle Cetrulo, Founder and CEO of AuxoCell Laboratories, a company specializing in solid tissue processing using its AC:Px System. In addition to heading Auxocell and being a thought-leader on perinatal stem cells, Kyle is an organizer for the upcoming 2nd Annual Perinatal Stem Cell Society Conference that will take place each March in Aspen, CO.
[Read more…]
Cynata’s iPSC-derived Cell Therapeutic
(CYP-001) Meets Safety & Efficacy Endpoints
Cynata Therapeutics Ltd (ASX: CYP) is a clinical stage regenerative medicine company specializing in stem cell therapeutics that has a proprietary technology for manufacturing induced pluripotent stem cell (iPSC) derived mesenchymal stem cells (MSCs). Cynata is the only company in the world that can mass-produce therapeutic mesenchymal stem cells deriving from a single donor at a consistent quality and affordable cost. [Read more…]
Preliminary Results From BioCardia’s Phase III Pivotal CardiAMP Heart Failure Trial Reported In Circulation Research Journal
SAN CARLOS, Calif., Aug. 22, 2018 — In a Viewpoint paper published online today in Circulation Research, the Phase III CardiAMP Heart Failure Trial (CardiAMP-HF Trial) studying the investigational CardiAMP stem cell therapy from BioCardia®, Inc. (OTC: BCDA) was highlighted as an example of personalized medicine, with promising results from the first 10 patients in the roll-in cohort reported. The company believes this to be the first outcomes data published from any pivotal trial of a stem cell therapy for heart failure. The paper is authored by Peter Johnston, M.D., Eric Duckers, M.D., Ph.D., Amish Raval, M.D., Thomas Cook, Ph.D. and Carl Pepine, M.D. [Read more…]
Could NiCord® by Gamida Cell Introduce a Paradigm Shift to HSCT?
Gamida Cell is an Israeli company specializing in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. The company is developing a diverse clinical pipeline based on its proprietary NAM technology platform. It lead program, NiCord®, is now in Phase 3 development for allogeneic bone marrow transplantation.
NiCord® was granted Breakthrough Therapy Designation by the FDA, as well orphan drug designation by the European Medicines Agency (EMA). [Read more…]
Steminent Announces Japan partner ReproCELL has PMDA Approval of CTN for Phase II Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia in Japan
San Diego, CA, USA, August 1st, 2018 – Steminent Biotherapeutics Inc. (“Steminent” or “Company”) a private, clinical-stage cell-therapy company with offices in Taiwan, San Diego and Shanghai, is pleased to announce that the Clinical Trial Notification (“CTN”), submitted by their Japan partner; ReproCELL, to the Japan Pharmaceuticals and Medical Device Agency (“PMDA”) for a Stemchymal® SCA Phase II clinical trial for Polyglutamine Spinocerebellar Ataxia (“PolyQ SCA”) has been approved. This is another key milestone for Steminent’s international Stemchymal® SCA Phase II clinical development program with trials now moving ahead in Taiwan, US, and Japan. [Read more…]
- « Previous Page
- 1
- …
- 109
- 110
- 111
- 112
- 113
- …
- 201
- Next Page »